Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients

Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpressi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CNS Oncol
Hlavní autoři: Le Rhun, Emilie, Chamberlain, Marc C, Zairi, Fahed, Delmaire, Christine, Idbaih, Ahmed, Renaud, Florence, Maurage, Claude Alain, Grégoire, Valérie
Médium: Artigo
Jazyk:Inglês
Vydáno: Future Medicine Ltd 2015
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6083940/
https://ncbi.nlm.nih.gov/pubmed/26498130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.30
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky